Similarly, Chahkandi et al. (2023) observed a reduction from 58.72 ± 32.16 U/L to 42.2 ± 20.2 U/L (p = 0.003), and Hashemi et al. (2009) documented a decrease from 113.03 IU/mL to 73.14 IU/mL (P = 0.001) in NASH patients, with ALT normalization achieved in 52% of the silymarin group compared to 18% in the placebo group (P = 0.001) [8,9]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.